Cytomx Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by Cytomx Therapeutics, Inc. on June 16, 2021. The filing details the voting results for four proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
On the record date of April 19, 2021, there were 65,004,227 shares of common stock outstanding. A total of 53,142,447 shares were voted at the meeting. The results for the proposals were as follows:
- Proposal 1 (Election of Class III Directors): Stockholders elected James R. Meyers and Halley Gilbert to the Board of Directors. Both nominees received significant support, though a notable portion of votes were cast against them.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Proposal 3 (Executive Compensation): Stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific vote counts against the director nominees, as over 16 million votes were cast against each Class III nominee.
- Confirm the total number of shares outstanding (65,004,227) versus shares voted (53,142,447) to assess shareholder engagement levels.
- Review the Definitive Proxy Statement on Schedule 14A filed on April 28, 2021, for detailed biographies of the elected directors and the full executive compensation report.